A near-infrared fluorescent probe activated by a dual-lock tandem activation of nitroreductase and aminopeptidase N, its preparation method and application

The near-infrared fluorescent probe activated by the dual-locking tandem activation of nitroreductase and aminopeptidase N solves the problem of low contrast of traditional probes, and achieves high specificity identification and precise resection of tumors and normal tissues, which is suitable for intraoperative navigation of tumors.

CN123106478APending Publication Date: 2026-11-17HEBEI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611422324.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing near-infrared fluorescent probes activated by single biomarkers have low contrast between tumors and normal tissues, are prone to generating false positive signals, and are difficult to meet the need for real-time definition of tumor boundaries during surgery.

Method used

A near-infrared fluorescent probe with dual-lock tandem activation of nitroreductase and aminopeptidase N was designed. It is cascaded activated only in tumor microenvironments where NTR and APN are simultaneously highly expressed. Through the tandem connection of nitrobenzyloxycarbonyl and L-alanyl groups, a "dual-lock structure" is formed, which produces strong near-infrared fluorescence under the combined action of NTR and APN.

Benefits of technology

It significantly improves the accuracy of tumor identification and the reliability of intraoperative navigation, reduces false positive signals, and provides a high signal-to-noise ratio for distinguishing tumors from normal tissues, making it suitable for preoperative tumor localization, intraoperative boundary delineation, and precise resection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106478A_ABST
    Figure CN123106478A_ABST
Patent Text Reader

Abstract

This invention provides a near-infrared fluorescent probe activated by a dual-lock tandem of nitroreductase and aminopeptidase N, its preparation method, and its applications. The fluorescent probe uses an isophorone-malononitrile-based near-infrared fluorophore (DCM) as the reporter unit, sequentially linked by an L-alanyl group and a p-nitrobenzyloxycarbonyl group. The fluorescent probe is activated only in tumor microenvironments where both NTR and APN are highly expressed, releasing DCM and producing strong near-infrared fluorescence at 656 nm. Experiments show that the fluorescent probe has strong specificity for tumors with high expression of both NTR and APN, distinguishing tumors from normal tissues. It shows promising application prospects in the preparation of tumor diagnostic reagents or intraoperative navigation imaging reagents for tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of fluorescent probe and biomedical imaging technology, and in particular relates to a near-infrared fluorescent probe that is activated by a dual-lock tandem activation of nitroreductase and aminopeptidase N, its preparation method and application. Background Technology

[0002] Accurate tumor detection and intraoperative real-time imaging are key to improving the complete tumor resection rate and reducing postoperative recurrence rate. Commonly used clinical imaging methods include magnetic resonance imaging, positron emission tomography (PET), computed tomography (CT), and ultrasound imaging. However, these methods generally have limitations such as insufficient sensitivity or spatial resolution, long detection time, and the risk of ionizing radiation exposure, making it difficult to meet the need for real-time intraoperative tumor boundary definition.

[0003] Near-infrared fluorescence imaging has become an important tool for intraoperative navigation due to its advantages such as non-invasiveness, high spatial resolution, rapid signal acquisition, and large tissue penetration depth. However, traditional "constant-brightness" near-infrared fluorescence probes have low contrast between tumors and normal tissues, which easily generates false positive signals, limiting their application in precision surgery.

[0004] Therefore, tumor microenvironment-responsive, activatable near-infrared fluorescent probes have attracted widespread attention. Typical characteristics of the tumor microenvironment include hypoxia, weak acidity, high reducing activity, and overexpression of multiple enzymes. Among these, nitroreductase (NTR) expression is significantly increased under hypoxic conditions, and its expression level is positively correlated with the degree of tumor hypoxia. Aminopeptidase N (APN), a zinc-dependent metallopeptidase, specifically hydrolyzes the N-terminal alanine residue of peptide chains, and its overexpression is closely related to tumorigenesis, angiogenesis, invasion, and migration.

[0005] Currently, probes activated by a single biomarker may still experience off-target activation due to low levels of target expression or non-specific reactions in normal tissues, leading to false positives. Therefore, there is an urgent need for a dual-locked tandem near-infrared fluorescent probe that can only be activated when two tumor-specific biomarkers are present simultaneously, in order to improve the accuracy of tumor identification and the reliability of intraoperative navigation. Summary of the Invention

[0006] In view of this, to solve the above problems, this invention proposes a near-infrared fluorescent probe that is activated by a dual-lock tandem activation of nitroreductase and aminopeptidase N, its preparation method, and its application. The fluorescent probe is cascaded activated only in tumor microenvironments where both NTR and APN are simultaneously highly expressed, exhibiting strong specificity in recognizing tumors with high NTR / APN expression. This allows it to distinguish tumors from normal tissues, effectively improving the accuracy of tumor identification and the reliability of intraoperative navigation.

[0007] To achieve the above objectives, the technical solution of the present invention is implemented as follows:

[0008] This invention discloses a near-infrared fluorescent probe that is activated by a double-locked tandem activation of nitroreductase and aminopeptidase N, wherein the fluorescent probe is a compound having the structure shown in formula (I) (NTR-APN-DCM) or a pharmaceutically acceptable salt thereof:

[0009] (I);

[0010] Molecular formula: C 30 H 29 N5O5; Molecular weight: 539.59.

[0011] In some preferred embodiments of the fluorescent probe of the present invention, the fluorescent probe uses the isophorone-malononitrile-based near-infrared fluorophore DCM as the fluorescent core, and connects L-alanyl and p-nitrobenzyloxycarbonyl in series at the 4-amino site of DCM, wherein the p-nitrobenzyloxycarbonyl constitutes the first lock for NTR response and the L-alanyl constitutes the second lock for APN response.

[0012] The fluorescent probe uses (E)-2-(3-(4-aminostyryl)-5,5-dimethylcyclohex-2-en-1-yl)malonadionitrile (DCM) as the near-infrared fluorescent reporter unit, with an L-alanyl group and a p-nitrobenzyloxycarbonyl group sequentially tandemly introduced at its 4-amino site. The p-nitrobenzyloxycarbonyl group acts as the first lock for the nitroreductase NTR response, and the L-alanyl group acts as the second lock for the aminopeptidase NAPN response, forming a "double-lock tandem" activatable structure.

[0013] The activation mechanism of the fluorescent probe is as follows: In the tumor microenvironment where NTR and APN are simultaneously highly expressed, NTR first reduces the nitro group in p-nitrobenzyloxycarbonyl to an amino group, triggering a 1,6-self-elimination reaction to generate the non-fluorescent intermediate APN-DCM; subsequently, APN specifically hydrolyzes the amide bond between the L-alanyl group and DCM, releasing the free fluorophore DCM. Due to the enhanced intramolecular charge transfer effect of DCM, it produces strong near-infrared fluorescence at 656 nm under 465 nm excitation, thereby achieving tumor-specific imaging;

[0014] The intermediate APN-DCM has the structure shown in formula (II):

[0015] ;

[0016] Its chemical name is (E)-2-(3-(4-((S)-2-aminopropamido)styryl)-5,5-dimethylcyclohex-2-en-1-yl)malononitrile, and its molecular formula is C2. 22 H 24N4O, molecular weight 360.46.

[0017] The second aspect of this invention discloses a method for preparing a near-infrared fluorescent probe activated by a double-locked tandem activation of nitroreductase and aminopeptidase N, the preparation route of which is as follows:

[0018] .

[0019] In some preferred embodiments of the preparation method of the present invention, the following steps are included:

[0020] S1. Isophorone and malononitrile were refluxed in anhydrous ethanol under the catalysis of piperidine and glacial acetic acid to obtain intermediate NA-01.

[0021] S2. NA-01 and p-acetaminobenzaldehyde were refluxed in anhydrous ethanol under the catalysis of piperidine and glacial acetic acid to obtain intermediate NA-02.

[0022] S3. NA-02 is refluxed in an ethanol-concentrated hydrochloric acid system to remove the acetyl group, yielding intermediate NA-03 (fluorophore DCM).

[0023] S4. NA-03 and tert-butoxycarbonyl-L-alanine are condensed in a phosphorus oxychloride-anhydrous pyridine system to obtain intermediate NA-04.

[0024] S5. Remove the tert-butyloxycarbonyl protecting group from NA-04 with trifluoroacetic acid to obtain intermediate NA-05;

[0025] S6. NA-05 and 4-nitrobenzyl chloroformate were subjected to a substitution reaction under N,N-diisopropylethylamine conditions to obtain the fluorescent probe NTR-APN-DCM (NA-06).

[0026] In some preferred embodiments of the preparation method of the present invention, in S1, the molar ratio of isophorone to malononitrile is 1:1, the amount of anhydrous ethanol is 5 mL of anhydrous ethanol per millimol of isophorone, the amount of piperidine is 25 μL of piperidine per millimol of isophorone, and the amount of glacial acetic acid is 25 μL of glacial acetic acid per millimol of isophorone.

[0027] In S2, the molar ratio of NA-01 to N-(4-formylphenyl)acetamide is 1:1, the amount of anhydrous ethanol used is 7.5 mL of anhydrous ethanol per millimol of NA-01, the amount of piperidine used is 25 μL of piperidine per millimol of NA-01, and the amount of glacial acetic acid used is 25 μL of glacial acetic acid per millimol of NA-01.

[0028] In S3, the amount of anhydrous ethanol used is 5 mL of anhydrous ethanol per millimole of NA-O2, and the amount of concentrated hydrochloric acid used is 10 mL of concentrated hydrochloric acid per millimole of NA-O2.

[0029] In S4, the molar ratio of NA-03, N-tert-butoxycarbonyl-L-alanine, and phosphorus oxychloride is 1:1:1, and the amount of anhydrous pyridine used is 6~7 mL of anhydrous pyridine per millimole of NA-03; the reaction is carried out at 0℃ for 0.5 h.

[0030] In step S5, NA-04 is dissolved in dichloromethane, and the tert-butyloxycarbonyl protecting group is removed with trifluoroacetic acid, wherein the volume of trifluoroacetic acid is equal to that of dichloromethane; the reaction is carried out at 0°C for 30 min.

[0031] In S6, the molar ratio of NA-05, 4-nitrobenzyl chloroformate and N,N-diisopropylethylamine is 1:1:4, and the amount of anhydrous N,N-dimethylformamide used is 20 mL of anhydrous N,N-dimethylformamide per millimole of NA-05.

[0032] In S1 to S6, the reaction was carried out under nitrogen protection, and the reaction was monitored by thin-layer chromatography until the raw material disappeared.

[0033] The third aspect of this invention discloses the application of a near-infrared fluorescent probe activated by a double-locked tandem of nitroreductase and aminopeptidase N in the preparation of tumor diagnostic reagents or intraoperative tumor navigation imaging reagents.

[0034] In some preferred embodiments of the present invention, the reagent is used for preoperative tumor localization, intraoperative tumor boundary delineation, and / or precise tumor resection under fluorescence navigation.

[0035] In some preferred embodiments of the present invention, the tumor is a solid tumor that simultaneously highly expresses NTR and APN.

[0036] In some preferred embodiments of the present invention, the solid tumor is at least one of renal cell carcinoma, lung cancer, and colon cancer.

[0037] In some preferred embodiments of the present invention, the reagent is administered via intravenous injection or local in-situ spraying.

[0038] The fourth aspect of this invention discloses an intraoperative fluorescence navigation imaging kit for tumors, comprising the fluorescent probe (NTR-APN-DCM), a pharmaceutically acceptable solvent or carrier, and a nitroreductase coenzyme.

[0039] Compared with existing technologies, the near-infrared fluorescent probe activated by nitroreductase and aminopeptidase N dual-lock tandem as described in this invention, its preparation method, and its application have the following advantages:

[0040] (1) The dual-lock tandem activation mechanism of the fluorescent probe described in this invention enables the probe to generate strong near-infrared fluorescence only when NTR and APN are present at the same time, which effectively reduces off-target and false positive signals caused by single marker activation and significantly improves the signal-to-noise ratio of tumor and normal tissue.

[0041] (2) The fluorescent probe of the present invention releases a fluorophore DCM after activation, which has a significant intramolecular charge transfer effect and a maximum emission wavelength in the near-infrared region of 656 nm, which is beneficial for deep tissue imaging and real-time intraoperative navigation.

[0042] (3) The preparation method described in this invention is simple, the raw materials are readily available, all six steps are conventional unit operations and do not require special equipment, and the yield of each step is above 67% (67.44%~83.67%). The intermediates and the final products are confirmed by nuclear magnetic resonance hydrogen spectrum, carbon spectrum and high resolution mass spectrometry, and the purity is analyzed by high performance liquid chromatography, which is suitable for scale-up preparation.

[0043] (4) The fluorescent probe described in this invention has good biocompatibility and has little effect on the survival rate of various cells in the concentration range of 0.08~160μmol / L; in vivo experiments, there is no obvious histological damage to major organs and the safety is good.

[0044] (5) The fluorescent probe described in this invention can be administered via intravenous injection and in situ spraying. It can be used for preoperative tumor localization and can also be used directly for intraoperative tumor boundary delineation and precise resection. Its ability to distinguish between cancerous and normal tissues has been verified on fresh clinical specimens of human renal cancer, and it has good prospects for clinical translation. Attached Figure Description

[0045] Figure 1 The proton nuclear magnetic resonance spectra (400 MHz) of compounds NA-01 to NA-06 in DMSO-d6 solvent are shown.

[0046] Figure 2 The carbon nuclear magnetic resonance spectra (101 MHz) of compounds NA-01 to NA-06 in DMSO-d6 solvent are shown.

[0047] Figure 3 In vitro spectral characterization of the fluorescent probe NTR-APN-DCM; among which, Figure 3 a is a schematic diagram of NTR-APN-DCM being activated by the cascaded connection of NTR and APN; Figure 3 b represents the emission spectra of NTR-APN-DCM and DCM; Figure 3 c represents the near-infrared fluorescence spectrum of NTR-APN-DCM under the conditions of NTR (0.2 μg / mL), APN (1.0 μg / mL), and NTR+APN co-existing. Figure 3d shows the high-performance liquid chromatograms after NTR-APN-DCM was incubated with NTR, APN, and NTR+APN, respectively; Figure 3 e represents the fluorescence intensity of NTR-APN-DCM after incubation with different substances; Figure 3 f represents the liquid chromatography-mass spectrometry detection of NTR-APN-DCM in MCF7 cells under hypoxic conditions (1% O2); Figure 3 g represents the liquid chromatography-mass spectrometry detection of NTR-APN-DCM in LLC cells under hypoxic conditions (1% O2);

[0048] Figure 4 Cell viability of LLC, 4T1, MCF7, and HEK293 cells treated with NTR-APN-DCM at different oxygen concentrations; among them, Figure 4 Under conditions of 21% oxygen; Figure 4 b is under conditions of 1% oxygen;

[0049] Figure 5 In vitro imaging of LLC, 4T1, MCF7 and HEK293 cells treated with NTR-APN-DCM under hypoxic conditions;

[0050] Figure 6 Real-time near-infrared fluorescence imaging and biodistribution map of LLC tumor-bearing mice in vivo; among which, Figure 6 a is a diagram showing the interaction between NTR and APN in tumor tissue and NTR-APN-DCM activation (excitation wavelength λex=465nm, emission wavelength λem=660nm). Figure 6 b shows fluorescence imaging of ex vivo organs 6 hours after drug administration. Figure 6 c is Figure 6 Statistics on the relative fluorescence intensity corresponding to a and 6b;

[0051] Figure 7 Two tumor resection protocols under fluorescence navigation were proposed: tail vein injection and in-situ spraying. Figure 7 a is a schematic diagram of NTR-APN-DCM in situ spray drug delivery and intravenous injection-guided tumor resection; Figure 7 b shows the near-infrared fluorescence imaging results before and after the procedure following spray administration and intravenous injection of NTR-APN-DCM (tumor location is marked by a red circle). Figure 7 c is an ex vivo imaging image of the removed tumor tissue and various organs (liver, spleen, lung, heart, kidney, intestine); Figure 7 d represents the quantitative analysis of near-infrared fluorescence signals of major organs after dissection in the intravenous injection group and the spray administration group; Figure 7 e represents the quantitative detection of the content of DCM, the NTR-APN-DCM release product, in tumor tissue using high performance liquid chromatography, with a retention time tR = 16.93 min;

[0052] Figure 8 Near-infrared fluorescence imaging and differentiation of cancerous / normal tissue in clinical specimens of human renal cell carcinoma; among them... Figure 8 'a' represents the experimental flowchart; Figure 8 b is a near-infrared fluorescence image showing the changes over time of freshly isolated tissue after incubation with NTR-APN-DCM; Figure 8 c is an image of the tumor boundary in human renal cell carcinoma tissue; Figure 8 d is Figure 8 b corresponds to the relative fluorescence intensity; Figure 8 e represents the quantitative analysis of the content of DCM, the NTR-APN-DCM release product, in human renal cell carcinoma tissue using high performance liquid chromatography, with a retention time tR = 16.93 min.

[0053] Note: Statistical markers: *p < 0.05, **p < 0.01, ***p < 0.001. Detailed Implementation

[0054] Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as commonly understood by those skilled in the art. Unless otherwise specified, the experimental reagents used in the following embodiments are conventional biochemical reagents; and the experimental methods described are conventional methods.

[0055] The present invention will now be described in detail with reference to the embodiments and accompanying drawings.

[0056] Example 1: Preparation of near-infrared fluorescent probe NTR-APN-DCM

[0057] The chemicals and biological reagents used in this embodiment are all commercially available products and were not further purified before use; 4-nitrobenzyl chloroformate, N-tert-butoxycarbonyl-L-alanine, N,N-diisopropylethylamine and trifluoroacetic acid were purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.

[0058] The near-infrared fluorescent probe NTR-APN-DCM, which is activated by a double-locked tandem activation of nitroreductase and aminopeptidase N, was synthesized according to the following synthetic route:

[0059]

[0060] Preparation of intermediate NA-01 (S1): Isophorone (2.7642 g, 20.0 mmol) and malononitrile (1.3212 g, 20.0 mmol) were dissolved in anhydrous ethanol (100 mL), and piperidine (500 μL) and glacial acetic acid (500 μL) were added. The mixture was refluxed at 80 °C overnight under nitrogen protection, and the reaction was monitored by thin-layer chromatography until the starting material disappeared. After cooling, the reaction solution was extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate for 2 h, and the organic layer was concentrated and recrystallized from ethanol to obtain a yellowish-white solid NA-01 (3.1169 g, yield 83.67%).

[0061] Preparation of intermediate NA-02 (S2): NA-01 (1.8626 g, 10.0 mmol) and p-acetaminobenzaldehyde (1.6318 g, 10.0 mmol) were dissolved in anhydrous ethanol (75 mL), and piperidine (260 μL) and glacial acetic acid (260 μL) were added. The mixture was refluxed at 80 °C for 12 h under nitrogen protection. After cooling to room temperature, the reaction solution was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate for 2 h, and purified by silica gel column chromatography after removing ethyl acetate under reduced pressure to obtain NA-02 (2.3826 g, yield 71.89%).

[0062] S3. Preparation of the fluorophore DCM (NA-03): NA-02 (1.6571 g, 5.0 mmol) was dissolved in a mixture of anhydrous ethanol (25 mL) and concentrated hydrochloric acid (50 mL). The mixture was refluxed at 75–80 °C under nitrogen protection until the starting solid was completely dissolved. The reaction was monitored by thin-layer chromatography to ensure complete reaction. Ethanol was removed by vacuum evaporation, followed by extraction with dichloromethane, washing with saturated sodium chloride solution, drying with anhydrous sodium sulfate for 2 h, filtration, and dichloromethane removal. The resulting product was purified by silica gel column chromatography to obtain black crystalline DCM (NA-03) (1.4469 g, yield 73.62%).

[0063] Preparation of intermediate NA-04 (S4): NA-03 (0.8681 g, 3.0 mmol) and N-tert-butoxycarbonyl-L-alanine (0.5676 g, 3.0 mmol) were dissolved in anhydrous pyridine (20 mL), and phosphorus oxychloride (0.4600 g, 3.0 mmol) was added. The mixture was stirred in an ice-water bath at 0 °C for 1 h under nitrogen protection. After the reaction was completed, the mixture was brought to room temperature, quenched with an appropriate amount of dilute hydrochloric acid solution, extracted three times with ethyl acetate, and the combined ethyl acetate phases were washed three times with saturated sodium chloride solution. The mixture was dried over anhydrous sodium sulfate, filtered, and the solvent was removed by evaporation under reduced pressure. The resulting product was purified by silica gel column chromatography to obtain NA-04 (0.9836 g, yield 71.18%).

[0064] Preparation of intermediate NA-05 (S5): NA-04 (0.4606 g, 1.0 mmol) was dissolved in anhydrous dichloromethane (20 mL), and an equal volume of trifluoroacetic acid was added. The mixture was stirred in an ice-water bath at 0 °C for 30 min under nitrogen protection. The reaction solution was poured into a saturated sodium bicarbonate solution, extracted three times with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate for 2 h, filtered, and the dichloromethane was removed by vacuum evaporation. The solution was then purified by silica gel column chromatography to obtain a yellow solid NA-05 (0.2470 g, yield 68.52%).

[0065] S6. Preparation of probe NTR-APN-DCM (NA-06): NA-05 (0.3605 g, 1.0 mmol) and 4-nitrobenzyl chloroformate (0.2156 g, 1.0 mmol) were dissolved in N,N-diisopropylethylamine (600 μL) and anhydrous N,N-dimethylformamide (20 mL). The mixture was stirred at 25 °C for 4 h under nitrogen protection. After the reaction was monitored by thin-layer chromatography to ensure complete reaction, the mixture was quenched with dilute hydrochloric acid solution, extracted three times with ethyl acetate, and the organic phases were combined and washed three times with saturated sodium chloride solution. The mixture was dried over anhydrous sodium sulfate for 2 h, and concentrated under reduced pressure to obtain a yellow crude product. This crude product was purified by silica gel column chromatography to obtain a yellow solid NTR-APN-DCM (0.3639 g, yield 67.44%).

[0066] Structural confirmation: The structures of the obtained intermediates NA-01 to NA-06 (NTR-APN-DCM) were confirmed by proton and carbon NMR spectroscopy, respectively. Figure 1 and Figure 2 The nuclear magnetic resonance (NMR) tests were performed at 25°C on a Bruker AV400 NMR spectrometer. 1 The HNMR observation frequency was 400 MHz. 13 The C NMR observation frequency was 101 MHz, with tetramethylsilane (TMS) as the internal standard and deuterated dimethyl sulfoxide (DMSO-d6) or deuterated chloroform (CDCl3) as the solvent. High-resolution mass spectrometry was performed on a quadrupole ion trap mass spectrometer equipped with a standard electrospray ionization source. Purity analysis was performed on an Agilent 1260 high-performance liquid chromatograph using an Agilent Zorbax SB-C18 reversed-phase column with acetonitrile / ultrapure water containing 0.05% (v / v) trifluoroacetic acid as the mobile phase.

[0067] Example 2: In vitro spectroscopic characterization and tandem activation verification of the fluorescent probe NTR-APN-DCM

[0068] The fluorescent probe NTR-APN-DCM was dissolved in PBS buffer (pH 7.4), and its absorption spectrum was recorded using a UV-Vis spectrophotometer. Its fluorescence emission spectrum was also measured. The results showed that the probe's maximum absorption wavelength in PBS was approximately 366 nm, and its maximum emission wavelength was approximately 536 nm, with a weak fluorescence signal at 536 nm. At the same concentration, the probe only exhibited a weak non-near-infrared emission peak, while the free fluorophore DCM showed significantly enhanced near-infrared emission at 656 nm upon excitation at 465 nm. Figure 3 a, b)

[0069] Determination of release curves: Working solutions of NTR (2.0 μg / mL, supplemented with 250 μmol / L NADH as a coenzyme) and APN (1.0 μg / mL) were prepared using PBS buffer. 1 mL of probe solution (100 μmol / L) was incubated with NTR (2.0 μg / mL), APN (1.0 μg / mL), or both, at 37℃ for 2 h. Samples were taken at time points of 5, 10, 15, 30, 45, 60, 75, 90, 105, and 120 min during incubation. The fluorescence intensity was used to analyze the release of DCM by the probe under the combined action of NTR and APN. The reaction solutions at different time points were injected into a high-performance liquid chromatograph (methanol / water system) for quantitative analysis. The results showed that the near-infrared fluorescence at 656 nm was almost unenhanced when NTR or APN was present alone; only when both NTR and APN were present did the probe produce significantly enhanced near-infrared fluorescence at 656 nm, and the fluorescence intensity increased with increasing probe concentration (0–80 μmol / L). Figure 3 c).

[0070] High-performance liquid chromatography monitoring showed that, under the action of NTR, the probe (retention time t) R =18.17 min) can release approximately 95% of the intermediate APN-DCM (t) within 90 min. R =12.89 min), but the fluorescence intensity of the reaction solution did not change significantly during this stage; after the addition of APN, APN-DCM further released more than 98% of the free DCM within 120 min (t R =16.93 min), while the near-infrared fluorescence of the reaction solution gradually increased. These results demonstrate that the probe exhibits a strict NTR / APN tandem-dependent activation characteristic, meaning that the first activation only generates a non-fluorescent intermediate, and a second activation is required to restore near-infrared fluorescence. Figure 3 d).

[0071] Example 3: In vitro selectivity and anti-interference ability of the fluorescent probe NTR-APN-DCM

[0072] The probe NTR-APN-DCM was incubated with PBS, gamma-glutamyl transferase (GGT), leucine aminopeptidase (LAP), urokinase plasminogen activator (uPA), glutathione (GSH), dithiothreitol (DTT), azo reductase (AzoR), ZnCl2, Na2S2O4, NTR, APN, and NTR+APN in their respective detection buffers at 37°C for 4 h, and the near-infrared fluorescence signals of each group were measured. The results showed that the probe produced a significant near-infrared fluorescence enhancement only when NTR and APN were present simultaneously; the fluorescence signal changes were negligible when other enzymes, reducing agents, or metal ions were present alone, demonstrating that the probe has excellent selectivity and anti-interference ability for NTR and APN. Figure 3 e).

[0073] Example 4 Intracellular HPLC and mass spectrometry verification of the activation mechanism of the fluorescent probe NTR-APN-DCM

[0074] MCF-7 cells (APN-negative) and LLC cells (APN-positive) were incubated with the probe NTR-APN-DCM under 1% hypoxia for 6 h. Cell lysates were collected for HPLC and high-resolution mass spectrometry analysis. In MCF-7 cells, the probe was reduced by NTR to the intermediate APN-DCM (t... R =12.89 min, ESI-MS m / z=360.1950), due to the lack of APN, the fluorescence signal was weak; in LLC cells, the probe was activated by the NTR and APN cascade and finally converted into free DCM (t R =16.93 min, ESI-MS m / z=289.1579), accompanied by significant near-infrared fluorescence enhancement. These results further confirm that the probe also follows the NTR / APN tandem activation mechanism within cells ( Figure 3 f, g).

[0075] Example 5: Cytotoxicity and Biocompatibility of the Fluorescent Probe NTR-APN-DCM

[0076] Cell culture: LLC, 4T1, MCF-7, and HEK293 cell lines were purchased from the American Type Culture Collection (ATCC) and cultured in DMEM medium containing 10% heat-inactivated fetal bovine serum, penicillin (100 U / mL), and streptomycin (100 μg / mL) in an incubator at 37°C, 5% CO2, and 95% air. All cell experiments were performed using cells in the logarithmic growth phase with approximately 75% confluence. For hypoxic culture, cells were transferred to a hypoxic incubator and cultured at 37°C, 1% O2, 5% CO2, and 94% N2 for 6–48 h, with half the medium changed every 1–2 days.

[0077] The cytotoxicity of the probe NTR-APN-DCM against the four cell types under normoxic (21% O2) and hypoxic (1% O2) conditions was evaluated using the standard MTT assay. Cells in logarithmic growth phase were seeded at 2.0 × 10³ cells / well in 96-well plates and incubated for 6 h under normoxic conditions to allow adhesion. After washing three times with PBS, DMEM medium containing probes at concentrations of 0, 0.08, 0.16, 0.32, 0.625, 1.25, 5, 10, 20, 40, 80, and 160 μmol / L was added to each well, and incubation continued for 48 h under either normoxic or hypoxic conditions. Subsequently, freshly prepared MTT solution (0.5 mg / mL, 100 μL) was added to each well, and incubation continued at 37°C for 4 h. The supernatant containing MTT was carefully aspirated, and DMSO (150 μL) was added to dissolve the formed crystals. After gentle shaking, the absorbance at 490 nm was measured using a microplate reader. Cell viability was calculated as the ratio of absorbance of the drug-treated group to that of the untreated group treated with culture medium only. Results showed that, within the range of 0.08–160 μmol / L, and under both normoxic and hypoxic conditions, the viability of all four cell types remained above 90%, demonstrating the probe's good biocompatibility and low cytotoxicity, laying the foundation for its real-time fluorescence imaging in live cells and in vivo. Figure 4 ).

[0078] Example 6: Specific imaging of the fluorescent probe NTR-APN-DCM in hypoxic tumor cells

[0079] MCF-7, HEK293 (APN-negative), LLC, and 4T1 (APN-positive) cells in logarithmic growth phase were seeded in 35 mm confocal culture dishes (1.0 × 10^3 cells / dish) and incubated overnight at 37°C. The culture medium was then replaced with fresh medium containing the NTR-APN-DCM probe (50 μmol / L), and the cells were incubated for 6 h at 37°C under both normoxic (21% O2) and hypoxic (1% O2) conditions. After washing the cells three times with PBS, the nuclei were contrast-stained using Hoechst 33342, and imaging was performed under the same experimental conditions using a laser confocal microscope. The excitation wavelength for the red channel of the DCM was 465 nm, and the emission and collection wavelength was 656 nm.

[0080] The results showed that in APN-positive LLC and 4T1 cells, near-infrared fluorescence intensity increased with decreasing oxygen concentration; while in APN-negative MCF-7 and HEK293 cells, the fluorescence signal was weak. Pretreatment of hypoxic (1% O2) cells for 1–2 h with the NTR inhibitor dicoumarol (100 μmol / L) or the APN inhibitor bestatin (100 μmol / L) followed by co-incubation with the probe for 6 h significantly inhibited fluorescence enhancement, further confirming that fluorescence enhancement depended on the activity of NTR and APN.

[0081] To further verify the APN-dependent activation mechanism, APN-overexpressing MCF-7 and HEK293 cell models were constructed. Western blot analysis showed that APN protein was successfully expressed within 48 h after transfection with the APN plasmid. Under normoxic conditions, the fluorescence of MCF-7 and HEK293 cells after incubation with the probe was negligible; however, under hypoxic conditions, the near-infrared fluorescence of APN-overexpressing MCF-7 and HEK293 cells was approximately 5.2-fold and 6.3-fold higher than that of control cells, respectively, demonstrating that the probe can accurately reflect the hypoxic level of APN-overexpressing tumor cells. Figure 5 ).

[0082] Example 7: Real-time near-infrared fluorescence imaging and biodistribution in LLC tumor-bearing mice

[0083] Seven-week-old female C57BL / 6 mice weighing 17–19 g were selected, and LLC cells (2.0 × 10⁵ cells / mouse, 100 μL serum-free culture medium) were subcutaneously injected into the right posterior back of the mice to establish a subcutaneous LLC xenograft model. Mice were anesthetized with 5% isoflurane before imaging. When the tumor volume reached approximately 50 mm³, the LLC-bearing mice were randomly divided into four groups (n=3): (i) PBS + probe group; (ii) NTR inhibitor + probe group; (iii) APN inhibitor + probe group; (iv) NTR inhibitor + APN inhibitor + probe group. Groups (ii) and (iv) received an NTR inhibitor (20 mg / kg) via tail vein injection 1 h before probe administration, while groups (iii) and (iv) received an APN inhibitor (20 mg / kg) via tail vein injection 1 h before probe administration. Subsequently, mice in each group were injected via tail vein with the probe NTR-APN-DCM (20 mg / kg) dissolved in PBS, and time-series near-infrared fluorescence imaging was performed from 0 to 9 h using the IVIS Spectrum in vivo imaging system at an excitation wavelength of 465 nm and an emission wavelength of 656 nm (660 nm detection channel of the imaging system).

[0084] The results showed that the near-infrared fluorescence signal in the tumor region gradually increased over time, reaching a peak at 6 h after drug administration. At the same time points, fluorescence signals were still detectable in the inhibitor-treated group, but significantly lower than those in the untreated group. Quantitative analysis showed that, compared with the untreated group, the maximum fluorescence intensity of the tumor was reduced by approximately 3.71-fold, 4.14-fold, and 7.05-fold in the APN inhibitor group, NTR inhibitor group, and dual inhibitor group, respectively, demonstrating that the activation of the probe in vivo depends on NTR and APN.

[0085] Mice were sacrificed 6 hours after drug administration, and major organs such as the heart, liver, spleen, lung, kidney, and intestine, as well as tumor tissue, were removed for in vitro near-infrared fluorescence imaging to assess the in vivo biodistribution of the probe. Results showed that near-infrared fluorescence was mainly concentrated in tumor tissue, and its fluorescence intensity was significantly higher than that of the inhibitor treatment groups (…). Figure 6 ).

[0086] Example 8: Precise tumor resection under fluorescence navigation

[0087] When the tumor volume of LLC tumor-bearing mice was approximately 50 mm³, they were randomly divided into a tail vein injection group and an in situ spraying group.

[0088] Tail vein injection group: Mice were anesthetized 3 h after receiving a tail vein injection of the NTR-APN-DCM probe (50 μL, 50 μmol / L). The skin at the tumor site was incised, and near-infrared fluorescence imaging was performed using the IVIS Spectrum imaging system. The tumor tissue exhibited significantly stronger near-infrared fluorescence than the surrounding normal tissue, clearly delineating the tumor boundary, which allowed for precise tumor resection. A second fluorescence imaging of the surgical area after resection showed no residual fluorescence signal.

[0089] In situ spraying group: After anesthetizing mice, the skin at the tumor site was incised to expose the tumor. The probe NTR-APN-DCM (50 μL, 50 μmol / L) was uniformly sprayed onto the tumor and surrounding tissue. Near-infrared fluorescence imaging was performed 30 min later. The strong fluorescence signal made the tumor margins clearly distinguishable and guided precise resection.

[0090] In vitro fluorescence imaging was performed on the excised tumor tissue and major organs. The fluorescence of the tumor tissue was significantly higher than that of the heart, liver, spleen, lungs, and kidneys. HPLC confirmed the release of free DCM from the tumor tissue. Figure 7 ).

[0091] Example 9: Precise Identification of Clinical Specimens for Human Renal Cell Carcinoma

[0092] To evaluate the clinical translational potential of the probe NTR-APN-DCM, freshly resected human renal cell carcinoma tissue and paired adjacent normal kidney tissue were collected. After washing the freshly excised renal cell carcinoma and adjacent normal kidney tissues with PBS, they were immediately immersed in Krebs-Henseleit solution containing 2% fetal bovine serum for preservation. A 50 μmol / L solution of the probe NTR-APN-DCM was sprayed onto the surface of the renal cell carcinoma and adjacent normal kidney tissue samples, and real-time near-infrared fluorescence imaging of the human tissue samples was performed using an IVIS Spectrum imaging system.

[0093] The results showed that renal cell carcinoma tissue exhibited gradually increasing near-infrared fluorescence over time after probe application, while the fluorescence signal in normal renal tissue was weak. The maximum fluorescence intensity in the tumor area was more than 20 times higher than that in normal renal tissue, and the probe could clearly delineate the tumor boundary, accurately distinguishing cancerous tissue from adjacent normal tissue. HPLC analysis confirmed the release of free DCM in renal cell carcinoma tissue. The above clinical sample experiments demonstrate that the probe can achieve highly specific near-infrared fluorescence imaging of human renal cell carcinoma tissue, possessing potential for clinical intraoperative navigation applications. Figure 8 ).

[0094] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A near-infrared fluorescent probe activated by a dual-lock tandem activation of nitroreductase and aminopeptidase N, characterized in that, The fluorescent probe is a compound having the structure shown in formula (I) or a pharmaceutically acceptable salt thereof: (I)。 2. The near-infrared fluorescent probe activated by nitroreductase and aminopeptidase N dual-lock tandem according to claim 1, characterized in that: The fluorescent probe uses the isophorone-malononitrile-based near-infrared fluorophore DCM as the fluorescent core, with L-alanyl and p-nitrobenzyloxycarbonyl groups sequentially linked in series at the 4-amino site of DCM. The p-nitrobenzyloxycarbonyl group constitutes the first lock for NTR response, and the L-alanyl group constitutes the second lock for APN response.

3. A method for preparing a near-infrared fluorescent probe activated by a double-locked tandem activation of nitroreductase and aminopeptidase N as described in claim 1 or 2, characterized in that, The preparation route is as follows: 。 4. The method for preparing the near-infrared fluorescent probe activated by nitroreductase and aminopeptidase N dual-lock tandem according to claim 3, characterized in that, Includes the following steps: S1. Isophorone and malononitrile were refluxed in anhydrous ethanol under the catalysis of piperidine and glacial acetic acid to obtain intermediate NA-01. S2. NA-01 and p-acetaminobenzaldehyde undergo a Knoevenagel condensation reaction in anhydrous ethanol under the catalysis of piperidine and glacial acetic acid to obtain intermediate NA-02. S3. NA-02 is deacetylated by reflux in an ethanol-concentrated hydrochloric acid system to obtain intermediate NA-03; S4. NA-03 was reacted with tert-butoxycarbonyl-L-alanine in a phosphorus oxychloride-anhydrous pyridine system to obtain intermediate NA-04. S5. Remove the tert-butyloxycarbonyl protecting group from NA-04 with trifluoroacetic acid to obtain intermediate NA-05; S6. NA-05 and 4-nitrobenzyl chloroformate were subjected to a substitution reaction under N,N-diisopropylethylamine conditions to obtain the fluorescent probe NTR-APN-DCM.

5. The method for preparing the near-infrared fluorescent probe activated by nitroreductase and aminopeptidase N dual-lock tandem according to claim 4, characterized in that: In S1, the molar ratio of isophorone to malononitrile is 1:1, the amount of anhydrous ethanol used is 5 mL of anhydrous ethanol per millimol of isophorone, the amount of piperidine used is 25 μL of piperidine per millimol of isophorone, and the amount of glacial acetic acid used is 25 μL of glacial acetic acid per millimol of isophorone. In S2, the molar ratio of NA-01 to N-(4-formylphenyl)acetamide is 1:1, the amount of anhydrous ethanol used is 7.5 mL of anhydrous ethanol per millimol of NA-01, the amount of piperidine used is 25 μL of piperidine per millimol of NA-01, and the amount of glacial acetic acid used is 25 μL of glacial acetic acid per millimol of NA-01. In S3, the amount of anhydrous ethanol used is 5 mL of anhydrous ethanol per millimole of NA-O2, and the amount of concentrated hydrochloric acid used is 10 mL of concentrated hydrochloric acid per millimole of NA-O2. In S4, the molar ratio of NA-03, N-tert-butoxycarbonyl-L-alanine and phosphorus oxychloride is 1:1:1, and the amount of anhydrous pyridine used is 6~7 mL of anhydrous pyridine per millimole of NA-03. In step S5, NA-04 is dissolved in dichloromethane, and the tert-butyloxycarbonyl protecting group is removed with trifluoroacetic acid, wherein the trifluoroacetic acid and dichloromethane are in equal volumes; In S6, the molar ratio of NA-05, 4-nitrobenzyl chloroformate and N,N-diisopropylethylamine is 1:1:4, and the amount of anhydrous N,N-dimethylformamide used is 10 mL of anhydrous N,N-dimethylformamide per millimole of NA-05. In S1 to S6, the reaction was carried out under nitrogen protection, and the reaction was monitored by thin-layer chromatography until the raw material disappeared.

6. The application of the near-infrared fluorescent probe activated by the nitroreductase and aminopeptidase N dual-lock tandem as described in claim 1 or 2 in the preparation of tumor diagnostic reagents or intraoperative tumor navigation imaging reagents.

7. The application according to claim 6, characterized in that: The reagent is used for preoperative tumor localization, intraoperative tumor boundary delineation, and / or precise tumor resection under fluorescence navigation.

8. The application according to claim 6, characterized in that: The tumor is a solid tumor that simultaneously highly expresses NTR and APN; Preferably, the solid tumor is at least one of renal cell carcinoma, lung cancer, and colon cancer.

9. The application according to claim 6, characterized in that: The reagent is administered via intravenous injection or local in-situ spraying.

10. A tumor intraoperative fluorescence navigation imaging kit, characterized in that: Includes the fluorescent probe of claim 1 or 2, a pharmaceutically acceptable solvent or carrier, and a nitroreductase coenzyme.